Modern research has shown that Amaryllidaceae alkaloids represent a rich reservoir of potential small chemical molecules exhibiting several medicinal properties through various mechanisms. Among the many Amaryllidaceae compounds, galanthamine has been given a great amount of attention due to the fact that it possesses potent acetylcholinesterase inhibitory activity. In spite of the amount of evidence indicating the potential usefulness of Amaryllidaceae alkaloids in therapy, research groups have focused their attention on the other alkaloids present in this plant family. New investigations have shed light on many aspects of the structure of Amaryllidaceae alkaloids and on their semisynthetic modification, function, and mechanisms underlying in vitro and in vivo activity. In addition, Amaryllidaceae alkaloids have frequently been identified as having promising cytotoxic properties against cancer cell lines. While followup studies have repeatedly shown that Amaryllidaceae alkaloids and their derivatives demonstrate antiproliferative, cytotoxic and apoptosis-inducing activity, the mechanisms remain unclear. This review addresses the most important Amaryllidaceae alkaloids with anticancer potential, particularly those that have been studied for the purpose of gaining a better understanding of the basis of the activity at the cellular and molecular level.
Cholinesterase inhibitors are the only approved drugs for therapy of patients with mild to moderately severe Alzheimer's disease [11] , one of the most common forms of dementia, characterized by progressive cognitive and functional impairment and memory loss [12] . Galanthamine can cross the blood-brain barrier and act within the central nervous system. It binds at the base of the activesite gorge of AChE and interacts with both the choline-binding site and the acyl-binding pocket [6] . In addition, galanthamine interacts with the nicotinic receptor at a binding site separate from those for acetylcholine and nicotinic agonists, and acts specifically to sensitize nicotinic receptors in the presence of acetylcholine. As the severity of cognitive impairment in Alzheimer's disease also correlates with loss of nicotinic receptors, this double effect appears to be beneficial for treating the disorder. Galanthamine absorption is rapid and complete, with the absolute oral bioavailability between 80 and 100% [10] .
Since galanthamine has allosteric potentiating effects at nicotinic receptors, it affects not only cholinergic transmission but also other neurotransmitter systems such as monoamines, glutamate and GABA by means of its allosteric mechanism. These effects make this compound useful not only in the treatment of Alzheimer's disease but also in some mental illnesses like schizophrenia and bipolar disorder [11] .
Other Amaryllidaceae alkaloids, such as sanguinine [6] , assoanine and oxoassoanine, have also been reported to possess AChE inhibitory activity [13] . Also of interest with regard to therapeutic intervention for Alzheimer's disease, numerous important bioactive compounds have been, and continue to be, isolated worldwide from Amaryllidaceae species. Recent development revealed that the alkaloid fraction from Crinum jagus, containing lycorine and vitattine as the main components, afforded significant neuroprotection against the excitotoxicity induced by glutamate in primary cortical neurons of rats. Significant reversing effects of glutamate-induced excitotoxicity were achieved at 2.9 µg/mL. Moreover, cerebral cortical neurons treated with glutamate plus alkaloidal fractions of C. jagus in post-treatment exhibited greater cell viability than cultures that were pre-treated with glutamate stand-alone. Furthermore, the alkaloid extracts from C. jagus and Zephyranthes carinata revealed an inhibitory activity against AChE. We refer to [14] for further details.
Lycorine: Lycorine, a pyrrolo[de]phenanthridine ring-type alkaloid extracted from Amaryllidaceae genera, possesses various biological effects including antitumor, antiviral, antimalarial and antiinflammatory activity [15, 16] , and is possibly neuroprotective against glutamate-induced excitotoxicity [14] . In 1877 it became the first metabolite isolated from different species of Lycoris [17] and its cytotoxic effect against cancer cells was first observed in 1920 by researchers from the National Cancer Institute (NCI) [18] . Although lycorine does not have a specific mechanism of action, it is a candidate anticancer and anti-inflammatory drug. For example, a drug containing lycorine as an effective component has been clinically used in Russia as an expectorant to treat chronic and acute inflammatory processes in the lungs and to treat bronchial diseases [19, 20] . Also, several studies have shown that lycorine can inhibit protein synthesis in eukaryotes [19] . Moreover, in vitro lycorine exhibits significant antiplasmodial activity against both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum with IC 50 values of 0.6 and 0.7 µg/mL respectively [3] .
When considering the antitumor activity in cancer cells, the study performed on the promyelocytic leukemia HL-60 cell line showed promising anticancer activity at concentrations ranging from 0.31 to 5 µM. Flow cytometry cell cycle analysis using propidium iodide DNA staining determined that lycorine is capable of arresting the cell cycle at the G2/M phase at 5 µM. It was also found that exposure to lycorine with the same concentration can induce apoptosis of leukemia cells via activation of caspase-8, caspase-9 and caspase-3, with the activation of caspase-3 being the most significantly increased [19] . Another in vitro study showed that incubation with lycorine at 5 µM is capable of cell cycle arrest in the chronic myelogenous leukemia K562 cell line at the G0/G1 phase via inhibition of histone deacetylases activity [21] . Furthermore, lycorine is capable of inducing apoptosis, probably through translational inhibition of the Mcl-1 protein, in U937 and 6T-CEM leukemia cell lines which were treated with higher concentrations of 10 μM [20] . Mcl-1 (myeloid cell leukemia-1) protein is a member of the Bcl-2 protein family and has been shown to be highly expressed in a variety of cancers, including certain forms of leukemia. It can act as an apical molecule in apoptosis control, promoting cell survival by interfering at an early stage in the cascade of events leading to the release of cytochrome c from mitochondria. This suggests that Mcl-1 plays a major role in suppressing apoptosis in various types of cancer cells [22] .
Later study was performed which focused on the effects of lycorine concentrations up to the 10 μM on multiple myeloma cell line ARH-77. This study revealed that lycorine can decrease proliferation through G1-phase cell cycle accumulation in ARH-77 cells. After further investigation of the regulatory mechanism leading to cell cycle arrest, it was determined that lycorine can decrease the protein levels of cyclin D1 and cyclin-dependent kinase 4 and increase the expression of the CDK inhibitor p21. The neutral Comet assay and the increased activation of the DNA double strand breaks (DSBs) marker γH2AX confirmed that lycorine can induce DNA damage at 10 μM. Similarly to lycorine, the DSBs are also induced by ionizing radiation and by radiomimetic agents which are often used in cancer therapy. Although lycorine had the ability to induce DNA damage such as ionizing radiation and some chemotherapeutic agents, inversely to conventional chemotherapeutic agents, it was also observed that Cytotoxicity of Amaryllidaceae alkaloids Natural Product Communications Vol. 11 (10) 2016 1589 lycorine causes programmed necrosis in the multiple myeloma ARH-77 cell line [23] .
A recent in vitro study by Hu et al. showed that lycorine inhibits the proliferation (IC 50 ranging from 5 µM to 10 µM), migration, invasion and survival of various prostate cancer cell lines, such as PC-3M, DU145, LNCaP, and 22RV1 [16] . This cellular response was associated with cell death via apoptosis, clear cleavage of caspase-3, Poly(ADP-ribose) polymerase (PARP) and the reverse process of epithelial-mesenchymal transition (EMT) in prostate cancer cell lines. Additional research efforts with in vivo experiments showed that the intraperitoneal administration (i.p.) of lycorine (5 mg/kg/day or 10 mg/kg/day) reduces both the weight and volume of ectopically implanted PC-3M subcutaneous xenografts by about 80% and exhibits no obvious systemic toxicity. When tested in the orthotopic xenograft model utilizing luciferaseexpressing (PC-3M-luc) cells, lycorine in a same dosage of 5 mg/kg/day or 10 mg/kg/day significantly inhibited prostate cancer cell growth and metastasis. Moreover, regarding molecular mechanisms in vitro, lycorine-treated hormone-refractory prostate cancer PC-3M cells at increasing concentrations (from 0 μM to 25 μM) prevented the activation of epidermal growth factor (EGF) induced JAK/STAT signalling and multiple STAT3 downstream targets, such as cyclin D1, Bcl-2, Bcl-xL, matrix metalloproteinase 2 and the EMT promoter Twist [13] . In a later experimental study, lycorine was shown to have an inhibitory effect on vasculogenic mimicry of melanoma cells, and is considered to be effective in suppressing neovascularization of ovarian cancer cells Hey1B in vivo [1] .
It is no surprise then that pharmaceutical preparations and semisynthetic derivatives of lycorine have attracted unprecedented interest and have been explored for potential anticancer activity in several types of cancer cells. For example, one in vitro study showed that the hydrochloride salt of lycorine selectively suppresses ovarian cancer Hey1B cell proliferation with an IC 50 1.2 ± 0.1 µM. This effect is attributable to its ability to inhibit the expression of cyclin D3 and to enhance the expression of the cell cycle inhibitor p21. In the same work, application of lycorine impeded the expression of key angiogenic genes, such as VEcadherin, vascular endothelial growth factor and Sema4D, and blocked Akt phosphorylation in Hey1B cells [24] . In addition, lycorine hydrochloride can inhibit melanoma C8161 cell-dominant vasculogenic mimicry by reducing VE-cadherin gene expression and diminishing cell surface exposure of the VE-cadherin protein in vitro. Furthermore, to test the antivasculogenic effect of lycorine hydrochloride in vivo, Matrigel was mixed with GFP-positive C8161 melanoma cells plus 7.5 or 15 µg of lycorine hydrochloride and were injected subcutaneously into the midventral abdominal region of nude mice. Thereafter, hematoxylin and eosin staining of the excised melanoma cell Matrigel plug sections from nude mice revealed that lycorine hydrochloride reduced the number of blood vessels in a dose-dependent manner. Taken together, and given the fact that vasculogenic mimicry has been reported to play an important role in cancer progression and metastasis, these findings highlight both the in vitro and in vivo potential of lycorine [5] .
Its analogue, pseudolycorine, displays a remarkable ability to increase the lifespan of leukemic mice infected with Rauscher virus when compared with standard leukemia drugs such as vincristine. Furthermore, Furusawa et al. showed that the combination of pseudolycorine with merkaptopurine or cyclophosphamide dramatically enhanced their efficacy in Rauscher leukemia mice compared with the administration of either drug alone [25] . In addition, no adverse effect on humoral antibody production was observed in mice exposed to pseudolycorine compared with the leukemia drug standards used in the study. Similar to lycorine, pseudolycorine also affects protein synthesis by eukaryotic ribosomes via inhibition of the key peptide bond formation step [18] .
Amarbellisine: Amarbellisine is a lycorine type alkaloid from Amaryllis belladonna L., a widely cultivated and naturalized ornamental plant. The data on the antiproliferative activity of amarbellisine exhibited a potent cytostatic effect against A549, OE21, Hs683, U373, SKMEL-28 and B16F10 cancer cells at concentrations ranging from 5 to 10 µM. Besides these, the results of antibacterial and antifungal screening showed that amarbellisine exhibited promising activity against Gram-negative Escherichia coli and the opportunistic yeast pathogen Candida albicans [4, 26] .
Ungeremine: This phenanthridine alkaloid, also known as lycobetaine, has been isolated as a minor constituent from several species of Amaryllidaceae and can also be prepared by oxidizing lycorine with selenium dioxide. Over the last four decades, studies have shown that ungeremine displays distinct physiological properties. In particular, ungeremine shows growth inhibitory effects and significant cytotoxic activity against Ehrlich ascites carcinoma, ascites hepatoma, Lewis lung carcinoma and Yoshida ascites sarcoma in mice or rats after i.p. application. In nude mice with subcutaneous xenografts of gastric cancer, ungeremine has extended the survival time and decreased tumor size after i.p. injection of 60 mg/kg/twice a week.
Later, Barthelmes et al. showed that ungeremine is able to interfere with the enzymatic activity of human topoisomerases [27] . These enzymes are involved in a number of crucial cellular processes, including replication, transcription (where they can change the topology of DNA by adding or removing supercoils) and recombination. Type I topoisomerase relaxes DNA (removes supercoils) by nicking and closing one strand of duplex DNA. Type II topoisomerase changes DNA topology by breaking and rejoining double-stranded DNA. This enzyme can introduce or remove supercoils and can separate two DNA duplexes that are intertwined. Topoisomerases are important in both growing fork movement and untangling finished chromosomes after DNA duplication [28] . Compounds with inhibitory activity against topoisomerase can inhibit these enzymes through altered topological distribution of DNA, or can poison them, which results in cryptic single and double strand breaks associated with the enzyme's covalent attachment to DNA. Consequently, the discovery of such drugs that target DNA of malignant cells is a major consideration when developing new drugs for the treatment of cancer [29] .
A further study performed by Barthelmes et al. on a model of calf thymus DNA incubated with pure recombinant human topoisomerases IIα and IIβ revealed that ungeremine is a topoisomerase II poison selective for the IIβ form of the enzyme [27] . Maximal depletions were obtained with 200 µM of ungeremine, whereas minor effects were seen at higher concentrations. Regarding anticancer activity, ungeremine was active against a mini-panel of human leukemia cell lines (HL-60, MOLT-4, K562, U937 and LXFL 529L) with a mean growth inhibitory value of IC 50 1.3 µM. Also, ungeremine i.p. administered (total dose 480 mg/kg) to athymic nude mice carrying subcutaneously implanted human gastric tumor xenograft GXF251 resulted in a marked delay in tumor growth 4 weeks post treatment when compared with non-treated control [27] .
Its natural analogue (+)-1-hydroxy-ungeremine, which is found in Lycoris radiata, displayed in vitro cytotoxic potential against CCF-STTG1 (astrocytoma), CHG-5 (glioma), SHG-44 (glioma), HL-60, SMMC-7721 (hepatocellular carcinoma) and W480 (colon cancer) cell lines with IC 50 values of 10.3 ± 0.9 µM, 10.2 ± 1.6 µM, 9.4 ± 1.3 µM, 10.8 ±1.6 µM, 10.5 ± 0.9 µM and 11.6 ± 1.1 µM, respectively [30] .
Haemanthamine: Haemanthamine belongs to the β-crinane-type of Amaryllidaceae alkaloids [31] . In Amaryllidaceae species this can be enzymatically converted to haemanthidine in an irreversible manner. Haemanthamine displays significant in vitro cytotoxic activity against several different types of cancer cell lines, including MOLT-4, HepG2, HeLa, MCF7, CEM, K562, A549 [32] , Caco-2, HT-29 [9] , A2780, SW1573 and T47-D [33] . In acute T-cell leukemia, Jurkat cell line exposure to haemanthamine (concentrations ranging from 5 to 20 µM) increased cell apoptosis and was accompanied by the activation of caspases 3, 7, 8 and 9, decreased mitochondrial membrane potential and arrested the cell cycle in the G1 and G2/M phase. The data obtained suggested that the occurrence of cell cycle arrest is due to haemanthamine's ability to alter cell cycle-regulatory proteins depending on p16 INK4a in the G1/S and Ser 345-phosphorylated form of Chk1 at G2/M checkpoint [32] . The overall mechanism of action supported by experimental evaluations is thought to be through protein synthesis inhibition, blocking the peptide bond formation step on the peptidyl transferase center of the 60S ribosomal subunit [34] . Additionally, a study performed on multidrug resistant L5178 mouse lymphoma cells demonstrated haemanthamine's capability to form complex formations with RNA, which results in a strong grow inhibitory effect at the cellular level [32] .
Recently, the pharmacokinetics of haemanthamine was estimated. It was administered to rats by means of an intravenous bolus at a dose of 10 mg/kg and the maximum observed plasma concentrations were reached within 4 minutes after the administration. The levels of haemanthamine thereafter showed a rapid, two-phase decline, which supports the idea that there are two compartments for distribution. However, the short duration of the distribution phase (only 30 minutes) suggests that equilibration between the compartments is quickly attained by means of passive diffusion. This notion is also supported by the identical concentrations of haemanthamine in plasma and bile at respective time points. The fast decline in plasma levels with a half-life of 70.4 ± 16.1 minutes in the second elimination phase confirms that this alkaloid does not tightly bind in tissue, but instead is swiftly eliminated from the organism. It was also revealed that haemanthamine is excreted by both bile and urine. While its concentration in bile was in line with those measured in plasma, the urinary level was higher by two orders of magnitude. Consequently, the urinary excretion of haemanthamine significantly dominated the biliary one and was more important for elimination. This suggests renal impairment as a possible risk factor for humans [35] .
Importantly for us, research on haemanthamine has uncovered other interesting medicinal properties. For example, haemanthamine was reported to have antioxidant activity quantified as scavenging action on pre-formed free radicals [32] , and has shown in vitro antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum with IC 50 1.3 µM [36] . This antiplasmodial activity can be attributed to the methylenedioxybenzene part of the haemanthamine molecule and to the tertiary nitrogen lacking methyl [6] . Moreover, haemanthamine and semisynthetic derivatives thereof displayed in vitro activity against influenza A virus N5H1 with EC 50 6.7 µM [5] .
Haemanthidine: Haemanthidine is another β-crinane type alkaloid derived from 5,10-β-ethanophenanthridine, which has gained attention as a possible anticancer agent. Early in vitro studies described its promising cytotoxic properties against A549, OE21, Hs683 and SKMEL cancer cells and its growth inhibitory effect on both parental and multidrug resistant L5178 mouse lymphoma cell lines [4, 37] . In Jurkat cell lines, haemanthidine displayed biological characteristics very similar to those of haemanthamine, as it was an effective compound in inhibiting cell proliferation, increasing apoptosis accompanied by caspases activation, decreasing mitochondrial potential and arresting cell cycle [32] .
It was also reported as being anti-inflammatory in mice and to have higher analgesic activity than aspirin or indomethacin [38] . Additionally, haemanthidine is cidal toward strains of chloroquinesensitive Plasmodium falciparum with IC 50 1.2 µM [36] , as well as toward Trypanosoma brucei rhodesiense and also, to a lesser extent, toward T. cruzi, in vitro [6] .
Recently the new structural analogue N-methylhaemanthidine (NMHC) was isolated from Zephyranthes candida. It was found that NMHC is capable of decreasing cell viability of multiple pancreatic cancer cell lines (AsPC-1, BxPC-3 and Mia PaCa-2) in a dose-dependent manner and possesses greater cytotoxic potential than gemcitabine and 5-fluoruracil. NMHC also causes cell cycle arrest at the G 2 /M phase, induces apoptosis, inhibits glucose metabolism and represses cell migration in the abovementioned pancreatic cancer cells. The molecular mechanism by which NMHC exerts its anticancer activity is, at least partially, through inhibition of the AKT signalling pathway of cell survival [39] .
Many compounds are developed experimentally directly as they are found in nature and others are derived from natural products by semisynthesis. Such natural and semisynthetic Amaryllidaceae alkaloids were prepared and evaluated in parallel by Cedrón and coworkers. The two semisynthetic compounds derived from haemanthidine and haemanthamine were found to be the most useful candidates (GI 50 ≤ 10 μM) as antiproliferative agents in a mini-panel of four (A2780, SW1573, T47-D and WiDr) human cancer cell lines. It is important to note, however, that both analogues were less active than their parent compounds [33] .
Bulbispermine: Bulbispermine is an α-crinane alkaloid obtained for the first time from the Amaryllidaceae plant Crinum bulbispermum [40] . In 2012 Luchetti et al. reported that bulbispermine at the concentration of 10 µM significantly inhibits the proliferation of apoptosis resistant glioblastoma cells T98G (GI 50 9 µM) and U373 (GI 50 38 µM) through cytostatic effects possibly arising from the rigidification of the cytoskeleton organization by increasing the amounts of polymerized actin [41] . Bulbispermine was also reported to have potent cytotoxic activity against human leukemia HL-60 cells [41] . In the study of Abdel-Halim et al. bulbispermine markedly inhibited NO production with IC 50 24 µM in lipopolysaccharide-activated mouse peritoneal macrophages [18] .
Distichamine:
The β-crinane alkaloid distichamine is extremely rare within the Amaryllidaceae, and current knowledge reveals that it is present only in Boophone disticha. Furthermore, the compound is unique amongst the crinane series of compounds in that it possesses both vinylic methoxyl as well as α,β-unsaturated ketone C-ring functionalities. Distichamine is biologically known to have a profound effect on the serotonin transporter [8] . Additionally, in recent years several studies have focused on its possible
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Natural Product Communications Vol. 11 (10) 2016 1591 anticancer activity. It was proved that distichamine exhibits micromolar in vitro activity against various human cell lines, such as HeLa, CEM, K562, MCF-7 and G-361 (IC 50 2.2 -14.7 µM), with the HeLa cell line shown to be the most sensitive (IC 50 2.2 µM). Upon further investigation, it was revealed that distichamine is also capable of cell cycle disturbance and apoptosis induction via activation of caspase 3 and 7 in CEM human leukemia cells [5, 8] .
Pretazettine: Pretazettine is a chemically labile precursor of tazettine and has received a lot of attention for its interesting antiviral, and, more importantly, anticancer properties. When it is stereochemically rearranged to tazettine, its biological activity is to a great extent inactivated. Studies have shown that pretazettine (IC 50 ranging from 4.12 to 8.85 µM) displays cytotoxicity against fibroblastic LMTK cell lines, inhibits cell growth of HeLa cells and is therapeutically effective against advanced Rauscher leukemia, Ehrlich ascites carcinoma, spontaneous AKR lymphoblastic leukemia and Lewis lung carcinoma. It is also one of the most active Amaryllidaceae alkaloids against MOLT-4 acute lymphoblastic leukemia cells [6] . Pretazettine exposure of human MDR1-gene-transfected L5158 mouse lymphoma significantly increased the intracellular concentration of rhodamine Rh-123 50fold and enhanced the antiproliferative activity of doxorubicin in the L5178 MDR cell line, thus indicating that pretazettine is capable of P-glycoprotein inhibition at the tested concentration of 400 µM in vitro [6, 42, 43] . It is equally important in the development of anticancer therapy, since P-glycoprotein is an energy-dependent efflux transporter driven by ATP hydrolysis and is overexpressed in a variety of tumor cells, where it is responsible for multidrug resistance by effluxing the administered drug out of the cell [44] .
Pretazettine can be used in combination therapy with DNA-binding and alkylating agents to treat the Rauscher leukemia virus. This compound also strongly inhibits the activity of reverse transcriptase from various oncogenic viruses by binding directly to the enzyme. It can negatively influence cellular host protein synthesis in eukaryotic cells by a mechanism that does not affect cellular RNA and DNA synthesis. Additionally, pretazettine displays activity against selected RNA-containing flaviviruses (for example dengue, yellow fever) and bunyaviruses in organ culture, and against Herpes simplex type 1 virus, which might reflect its general ability to inhibit protein synthesis during viral replication [6] . Narciclasine: Narciclasine was first isolated from Narcissus bulbs in 1967 by Ceriotti. Soon after the isolation of narciclasine, it was shown to exhibit a variety of inhibitory effects on plant growth, including seed germination, seedling growth, growth and plastid development of excised radish cotyledons (inhibiting the transition of glyoxysomes and peroxisomes), and chloroplast development [45] . Approximately 10 years after the discovery of narciclasine, Carrasco et al. provided the first evidence for narciclasine induced anticancer activity by showing that narciclasine inhibited eukaryotic ribosomal protein synthesis in rabbit reticulocytes [17] . More specifically, it was demonstrated that the inhibition of protein synthesis occurs through the narciclasine interaction with the 60S ribosome subunit. Narciclasine blocks peptide bond formation by preventing the binding of the 3'-terminal end of the donor peptide to the peptidyl transferase center [17] . Narciclasine can retard DNA synthesis as well, although it seems to be a secondary effect of narciclasine action [46] . In the NCI sixty cell line anticancer drug screen it exhibited a mean IC 50 value of 0.046 µM in vitro [18] . Narciclasine is also a potentially promising GTPase agent against brain tumors, including gliomas and brain metastases. Owing to its lipophilic properties, narciclasine (oral administration of 1 mg/kg/day) is actively transported from the bloodstream into the brain via an unknown mechanism, where it has exhibited cytostatic activity against human brain cancer xenografts in brains of immunocompromised mice. This isocarbostyril alkaloid has also induced profound modifications in glioma cell morphology, including actin cytoskeleton organization. The possible mechanism involves targeting both the Rho pathway and the elongation factor eEF1A, both of which play critical roles in actin cytoskeleton organization and functions involved in cell migration, cell morphology, protein synthesis, and cell death [17] . The evaluation of the growth-inhibitory properties has shown that narciclasine can decrease cancer cell proliferation and migration at concentrations >1 µM. Later, Lefranc et al. revealed that narciclasine impairs human glioblastoma multiforme cell (U373, Hs683 and GL19) proliferation by decreasing the mitosis rate, a process associated with a marked increase in the duration of mitosis [45] . Moreover, narciclasine also significantly modified the levels of migration of glioblastoma multiforme cells and induced actin polymerization. After the cells were treated with 100 nmol/L narciclasine, rapid and marked increase in the amount of fibrillary actin was observed in all cancer cell lines. When the actin-severing protein cofilin is an upstream regulator of actin polymerization in the pathway, narcilasine-induced modulation of cofilin activity was observed as well. Western blot analyses revealed rapidly increased levels of phospho-cofilin in U373, Hs683 and GL19 cell lines, while total cofilin levels remained unchanged. Cofilin, a regulator of actin filament dynamics, is known to be a substrate of phosphoserine/threonine protein kinases LIM (LIMK), acting downstream of Rho-associated protein kinase1 (ROCK1). Recent studies had indicated that the overall activity of the cofilin pathway determines the invasive and metastatic phenotype of tumor cells. Narciclasine significantly enhanced the expression of phospho-serine/threonine protein kinases, ROCK1 and phospho-LIMK1/2 in glioblastoma multiforme cells, which indicates that escalation of the amount of fibrillary actin observed during in vitro experiments may relate to narciclasine's activation of the cofilin pathway [45] .
Narciclasine is an inducer of the cell death in the cancer cells and produce lesser cytotoxic effect on the normal cells. The mean IC 50 value after 72 hours of treatment calculated for the six human cancer cell lines (A549, MCF-7, PC-3, LoVo, U373 and BxPC3) was 30 nM. The corresponding mean IC 50 value for the three fibroblasts cell lines (WI-38, CCD25Lu and WS1) was 7.5 µM. Furthermore, narciclasine can induce apoptosis in human prostate (PC-3) and breast (MDA-MB-231 and MCF-7) cancer cells, but not in normal fibroblast cells CCD25Lu. When cancer cells were treated with 1µM of narciclasine, dramatic morphological changes consistent with cell death were observed. Clear DNA laddering was visible after only 24 hours of treatment of PC-3 and MDA-MB-231 cells, and after 72 hours in the case of MCF-7 cells. The delay in DNA laddering in MCF-7 cells is likely due to the absence of caspase-3, which is thought to be the main caspase responsible for the processing of DNA fragmentation factor-45 (DFF45). Externalization of phosphatidylserine, an early apoptotic event as a result of the flipping of plasma membrane regions, was also investigated by means of double-labelling with Annexin V and propidium iodide (PI). In this study, the proportion of cells positive for Annexin V and negative for PI increased markedly in PC-3 and MDA-MB-231. Narciclasine treatment at 1 µM for less than 24 hours also caused loss of mitochondrial membrane potential, release of cytochrome c to the cytoplasm and activation of caspase 8 and/or caspase 10 in the PC-3 prostate and MCF-7 breast cancer cells evaluated. Caspase 8 and caspase 10 are the initiator caspases of the death receptor (extrinsic) pathway of apoptosis. Therefore the possible recruitment of caspase 8 by death receptors (FAS, DR4, Habartová et al.
DR5, and TNFR1) was also investigated. The Western blot analysis revealed that caspase 8 was recruited by the death receptors FAS and DR4, indicating the formation of death-inducing signaling complex (DISC) at the level of these two receptors [47] .
More recently, narciclasine's potent cytotoxic effects were described for HL-60 and HSC-2 cell lines with IC 50 0.018 and 0.05 µM, respectively. The proapoptotic activity was characterised by morphological changes, including condensation of chromatine, the ladder-like fragmentation of internucleosomal DNA, cell shrinkage and caspase-3 activation which were, in HL-60 human promyelocytic leukemia cells, more pronounced following treatment with narciclasine than with cisplatin, used as a positive control [18] .
Narcilasine was reported to show a prophylactic effect on the adjuvant arthritis model in rats, significantly suppressing the degree of swelling of adjuvant-treated and untreated feet. This alkaloid also exhibits activity against Corynebacterium fascians, Cryptococcus neoformans and some other RNA containing flaviviruses and bunyaviruses. Its derivative, 2,3,4,7-tetra-O-acetylnarciclasine, displays activity against the pathogenic bacterium Neisseria gonorrhoeae [6] . The only hurdle facing the progress of narciclasine on the clinical field remains its low aqueous solubility [18] .
Pancratistatin: Pancratistatin, a close structural analogue of narciclasine, was isolated from Hymenocallis littoralis in 1984 [48] . It has been shown to have antineoplastic and cytostatic activity. In 2004 Kekre et al. demonstrated its ability to induce apoptosis in human leukemia Jurkat cells at a concentration of 1 µM with no toxic effect on normal nucleated blood cells (lymphocytes) [49] . It was further revealed that pancratistatin-induced apoptosis was associated with caspase-3 activation, flipping of the phosphatidylserine-rich inner leaflet to the outer leaflet which faces the extracellular environment, production of reactive oxygen species and loss of mitochondrial membrane potential [49] . These findings were later confirmed on leukemic cells obtained from patients at the Windsor Regional Cancer Center [50] . When considering anticancer activity in human neuroblastoma SHSY-5Y cells, pancristatin (1 µM) induced an increase in the generation of reactive oxygen species and a decrease in the ATP cellular concentration [48] . In addition, pancratistatin promotes mitochondrial membrane permeabilization, which in turn causes apoptosis by releasing caspase activators and provokes the loss of essential mitochondrial function [17] . Similar features of pancratistatin mediated apoptotic death were also observed in androgen-sensitive human prostate LNCaP cells, androgenrefractory and p53 mutant human prostate DU145 cells [51] and in MCF-7 human breast cancer cell lines (IC 50 100 nM). In combination with the anti-estrogen anticancer drug Tamoxifen, pancrastatin treatment at 0.5 µM displayed a synergic effect against MCF-7 cell lines after a period of 72 hours [52] . Other studies have also shown the antitumor potential of pancratistatin. When tested on 5123tc rat hepatoma cells, pancratistatin induced apoptosis at a concentration of 1 µM in a time-dependent manner within a 48-hour interval. The main observed apoptotic features included cell shrinkage, DNA condensation and blebbing of cells. Moreover, pancratistatin was able to induce efficiently apoptotic cell death in skin carcinoma and human teratocarcinoma NT2 cell lines with no adverse effect on normal human fibroblasts [53] . While considering other biological properties, pancratistatin has also been found to exhibit strong RNA antiviral activity. Surprisingly, pancratistatin activity in vivo increased survival by 100% when it was used to treat mice infected with Japanese encephalitis. Furthermore, this compound showed activity against two other RNA-containing flaviviruses and bunyaviruses, namely Punta Toro and Rift Valley fever, and antiparasitic effects against microsporidium causing infections in humans [54] .
Recently, a new analogue, a C-1 acetoxymethyl derivative of 7deoxypancratistatin (JCTH-4), was produced by de novo synthesis. It exhibited selective cytotoxicity against human neuroblastoma (SH-SY5Y) and breast adenocarcinoma (MCF-7) cells at 1 µM concentration. In mitochondria isolated from the mentioned cancer cell lines, JCTH-4 caused dissipation of the mitochondrial membrane potential and an increase in reactive oxygen species production. These results suggest that JCTH-4 was able to induce apoptosis in both cell lines by mitochondrial targeting. Furthermore, treatment with JCTH-4 activated autophagy in MCF-7 cells. The addition of tamoxifen to JCTH-4 enhanced the aforementioned effects of JCTH-4 in SH-SY5Y and MCF-7 cells. Normal human fetal fibroblasts used as a control exhibited a marked decrease in sensitivity to JCTH-4 both alone and in combination with 10 µM tamoxifen [55] . A similar effect of JCTH-4 was also observed in human osteosarcoma cell lines Saos-2 and U-2 [56] .
Narciprimine: The first isolation of the phenanthridone alkaloid narciprimine was from an African Amaryllidaceae species, Cyrtanthus contractus. This alkaloid is also prominent amongst the genera Zephyranthes, Narcissus and Lycoris, endemic to the Americas, Europe and Asia, respectively. Narciprimine was found to exhibit micromolar inhibitory activity against AChE (IC 50 78.9 µM) [57] . Contrary to previous observations on the low cytotoxic potential of narciprimine, Nair et al. described its high activity against CEM cells [8] . Although its apoptotic effects were not as pronounced as other Amaryllidaceae alkaloids, narciprimine treated cells were characterised by a dose-dependent reduction in the number of G 1 and S cells and an increase in the proportion of G 2 /M phase cells, with a slight elevation of the sub-G 1 fraction at the 20 µM treatment. Moreover, procaspase-3 levels remained unchanged, while PARP cleavage was not detected over the range of concentrations tested. Additionally, expression of the antiapoptotic proteins Mcl-1 and Bcl-2 were unchanged. On the contrary, a dosedependent expression of the tumor suppressor protein p53 occurred over the 24 hours treatment period [18] . Narciprimine has also been investigated for its effects on DNA topoisomerase reactions. The results revealed that narciprimine (concentration ranging from 0.1 -0.25 µM) was effective in both type I and type II DNA topoisomerase reactions in a dose-dependent manner. The topoisomerase-interfering ability of this alkaloid partially correlated with antiproliferative activity determined against HeLa, MCF-7 and A341 cells using MTT assay [58] . On the other hand, narciprimine was also shown to be cytotoxic to noncancerous human fibroblast cells with an IC 50 value 7.9 µM [18] .
Overall, since Amaryllidaceae species have long been known for their toxicity and medicinal properties, there are undoubtedly many more unique and potent biologically active compounds waiting to be discovered. Recently, a new Amaryllidaceae alkaloid was described, isolated from the bulbs of Lycoris radiata. In this study, the new alkaloid, (+)-N-methoxylcarbonyl-2-demethylisocorydione, applied for 48 hours exhibited significant cytotoxic activities against tumor cell lines (CCF-STTG1, CHG-5, SHG-44, U251, HL-60, SMMC-7721, W480) in the micromolar range, except against meningioma cell line BEN-MEN-1 [30] .
In conclusion, several alkaloids derived from plants of the Amaryllidaceae have exhibited promising biological activity. These compounds likely contribute to the antitumor, antiplasmoidal, antiviral, antibacterial and AChE inhibitory activities. However, regarding the latter activity, in clinical practice only galanthamine in the form of its hydrobromide salt is used, and its usage is limited to treatment of Alzheimer's disease. The present literature review has summarized the results of studies focusing mainly on the anticancer potential of Amaryllidaceae alkaloids. These groups of alkaloids currently constitute a large and still expanding family of molecules with a great diversity of structure, some of which have negatively interfered with cancer cell proliferation and viability. In parallel to their potent antiproliferative activity in vitro they are capable of inducing apoptosis in various types of cancer cells with, at least to some extent, no cytotoxic effect on normal cells. Thus, Amaryllidaceae family alkaloids keep their potential as chemotherapeutic drugs, firstly because of their activity on chemoor radioresistant cancer cells at micromolar concentrations and secondly because of their very good tolerance for healthy cells giving them a larger therapeutic index in vitro. Altogether these observations have shown the potential of Amaryllidaceae alkaloids in anticancer therapy. Nowadays a wealth of data report cytotoxic activity in cancer cell lines, however, the exact mechanism of action of Amaryllidaceae alkaloid-induced cell death remains to be determined. Additionally, despite highly active research in this area, the data are still controversial concerning the possible mechanisms of action in different cancer cell lines used as experimental models. Therefore, further investigations are mandatory to understand better the cellular mechanisms in vitro as well as in vivo before initiating the next steps of clinical development.
